Kauliv
Teriparatide biosimilar developed by Strides Pharma. Reference product Forsteo (Forteo in the United States).
Brands by market: Kauliv (EU) · Commercial partner or holder: Strides Pharma · Company profile
FDANot listed
EMAJan 2023authorised
MHRALicenseddate not shown
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Approved or registered in 2 of 7 markets
Connections
About Kauliv
Kauliv is Strides Pharma's teriparatide, approved in Europe in January 2023 through Strides' Cyprus company. Strides is an Indian company better known for oral generics, and Kauliv is its first European biologic.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Kauliv
European Medicines Agency and European CommissionApprovedBrand
Kauliv
Holder or applicant
Strides Pharma (Cyprus) Limited
Pathway
Centralised (Article 10(4))
Approved
Jan 2023
Application or permission
EMEA/H/C/004932
Presentations
see SmPC
Source
S017 (EMA) · checked Sep 2026
MHRA
United Kingdom · Kauliv
Medicines and Healthcare products Regulatory AgencyApprovedBrand
Kauliv
Holder or applicant
Not shown in the MHRA substance list
Pathway
UK marketing authorisation (Great Britain and, for EU-converted licences, Northern Ireland)
Approved
not published
Presentations
20 micrograms/80 microlitres
Source
S023 (MHRA Products) · checked Sep 2026
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Kauliv holds an approval, these are the other teriparatide biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| EMA | 4 | CinnaGen (Zandoriah), Gedeon Richter (Terrosa / Movymia), Intas Pharmaceuticals (Sondelbay / Intas teriparatide), Not stated in the EMA table (Livogiva) |
| MHRA | 6 | Dr. Reddy's Laboratories (Teriparatide Dr. Reddy's), Gedeon Richter (Terrosa / Movymia), Intas Pharmaceuticals (Sondelbay / Intas teriparatide), Not stated in the MHRA list (Teriparatide Ambio Pharma), Sun Pharmaceutical Industries (Teriparatide Sun), Teva (Teriparatide Teva) |
Chronology
- EMAJan 2023Authorised by the European Commission as Kauliv
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)S023MHRA Products, substance lists of licensed medicines (products.mhra.gov.uk) Primary (regulator)
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.